Get started
Work

3070MO Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization

Year: 2025
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.annonc.2025.08.3684
Authors: A. Drakaki, S.H. Park, D.E. Castellano Gauna, A.O. Siefker-Radtke, M.A. Reimers, X. Gao, S.Y. Rha, M.D. Galsky, A. Tripathi, M. Sarfaty, R. Mamtani, T. Zhang, G.P. Sonpavde, A. Vinceneux, Y. Loriot, B. Garmezy, S. Szymczak, Z. Zhang, R. Widau, G. Iyer
Institutions: University of California, Los Angeles, Samsung Medical Center, Sungkyunkwan University, Hospital Universitario 12 De Octubre, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Harvard University, Massachusetts General Hospital, Yonsei University Health System, Yonsei Cancer Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, City Of Hope National Medical Center, City of Hope, Tel Aviv University, Sheba Medical Center, Abramson Cancer Center, University of Pennsylvania, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of Central Florida, Centre Léon Bérard, Université Paris-Saclay, Institut Gustave Roussy, Sarah Cannon, Eli Lilly (United States), Memorial Sloan Kettering Cancer Center
Language: English
Open Access status: bronze
OpenAlex ID: W4415940483
FWCI:
Cites:
Cited by:
Related to: